Job Assignment in Government Affairs establishing strategic relationships in governmental and legislative bodies, developing effective partnerships with governmental and civil institutions to promote the adoption of innovative practices, understanding and monitoring the access environment in relation to public and private markets, including updates from ATS/CONITEC, ANS, SUS, ANVISA.Bills and private payers, assessing scenarios and monitoring key governmental discussions and ensuring horizontal and vertical information flow within the organization.Work transversally with a cross-functional teams, including Brand Marketing, Market Access, Commercial, Legal, Gov Affairs and Patient Advocacy, Medical Affairs and Clinical Operations, in order to define key priorities aligned with brands strategies.Access tactical plan in key accounts and stakeholders from in a public market across MS and States, responsible for developing, implementing, and managing all aspects of activities based on market opportunities and responsible for broad and rapid access for the different pre-launch & mature brands by working closely with various internal functions Account Manager Public and Private and Market Access.Strong engagement with different payers in the states and municipalities levels, design & implement activities aligned with current public policy of health as well getting leverage points and triggers for access and using assistance programs.Brings an understanding of the Public payer perspective to the respective teams to ensure that public payer requirements are adequately met throughout the evidence development and commercial strategy development processes.Design, management and implement of local activities cross functionally.Delivery of robust, customized pharmacoeconomic value messages to payers to inform optimalhealth decision-making. Implement of economic models, payer dossiers and manuscripts to support the value proposition.Implement of specific health technology assessment dossiers in State and Municipal Incorporation of Blinatumumab in Hospital da Criança de Brasília, Incorporation of Denosumab in the PCDT of Osteporosis of SES GO, Incorporation of Romososumab in SES MA, Incorporation of Blinatumumab in IPASGO and collaboration on the Incorporation of Romosozumab and Blinatumumab in CONITEC.Finalist for the "Latam Group Awards" for Amgen's first state incorporation in Brazil.Awarded in the "Chairman Circle" (Rome) by AMGEN.Awarded for the best Kyprolis launch em 2016 (3o. Global Amgen)Awarded for the best Zytiga launch em 2012 (Janssen).